In adults with type 2 diabetes starting a second medicine after metformin, SGLT-2 inhibitors or GLP-1 drugs lowered the five-year risk of kidney decline vs. DPP-4 inhibitors in people with protein in…
In older US adults with fatty liver disease, starting a GLP-1 drug was linked to lower risks of liver decompensation (hazard ratio 0.72) and death (0.55), but not of major heart events,…
Among 14,118 matched pairs of adults with atrial fibrillation and type 2 diabetes, starting tirzepatide was linked to lower risks of stroke and death than starting another GLP-1 drug, with absolute differences…
